The estimated Net Worth of John Peter Walker is at least $157 millier dollars as of 11 April 2019. Mr. Walker owns over 100,000 units of Zosano Pharma Corp stock worth over $156,928 and over the last 21 years he sold ZSAN stock worth over $0. In addition, he makes $0 as Chairman of the Board at Zosano Pharma Corp.
John has made over 3 trades of the Zosano Pharma Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of ZSAN stock worth $350,000 on 11 April 2019.
The largest trade he's ever made was buying 100,000 units of Zosano Pharma Corp stock on 11 April 2019 worth over $350,000. On average, John trades about 11,306 units every 46 days since 2003. As of 11 April 2019 he still owns at least 280,228 units of Zosano Pharma Corp stock.
You can see the complete history of Mr. Walker stock trades at the bottom of the page.
John P. Walker is Chairman of the Board of the Company. He has served as a member of the Company’s Board since May 2016. While serving as Interim Chief Executive Officer, Mr. Walker will continue as Chairman of the Board. Mr. Walker is currently the Executive Chairman and interim Chief Executive Officer of Vizuri Health Sciences, LLC and served as a Managing Director of Four Oaks Partners, a life sciences transaction advisory firm, which he co-founded in March 2012, until January 2015. As part of his activities with Four Oaks Partners, Mr. Walker served as the Chairman and interim Chief Executive Officer of Neuraltus Pharmaceuticals, Inc., a privately held biopharmaceutical company, until October 2013. From February 2009 until July 2010, Mr. Walker was the Chief Executive Officer at iPierian, Inc., a company focused on the use of inducible stem cells for drug discovery. From 2006 until 2009, Mr. Walker served as the Chairman and Chief Executive Officer of Novacea, Inc., a pharmaceutical company, which merged with Transcept Pharmaceuticals, Inc., a pharmaceutical company, in January 2009. Since 2001, Mr. Walker, acting as a consultant, was Chairman and Interim Chief Executive Officer at Kai Pharmaceuticals, a pharmaceutical company, Guava Technologies, a biotechnology company, CentaurPharmaceuticals, Inc., a pharmaceutical company, and Bayhill Therapeutics, a biotechnology company. From 1993 until 2001, Mr. Walker was the Chairman and Chief Executive Officer of Arris Pharmaceutical Corporation, a pharmaceutical company, and its successor, Axys Pharmaceuticals Inc. He currently serves on the board of directors of Lucille Packard Children’s Hospital at Stanford University. He is a graduate of the Advanced Executive Program at The Kellogg School of Management at Northwestern University and holds a B.A. from the State University of New York at Buffalo.
John's mailing address filed with the SEC is C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT, CA, 94555.
Over the last 10 years, insiders at Zosano Pharma Corp have traded over $5,506,679 worth of Zosano Pharma Corp stock and bought 790,627 units worth $1,835,090 . The most active insiders traders include M James Barrett, Enterprise Associates 12, L... et Steve Elms. On average, Zosano Pharma Corp executives and independent directors trade stock every 60 days with the average trade being worth of $44,258. The most recent stock trade was executed by Christine Matthews on 6 June 2022, trading 82 units of ZSAN stock currently worth $58.
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company's transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano's lead product candidate is Qtrypta™ (M207), which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine.
Zosano Pharma Corp executives and other stock owners filed with the SEC include: